The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Lorlatinib) in health participants. This study is seeking participants who:
Must be male or female of non-child bearing potential of 18 to 75 years of age, inclusive at the time of the study.
Are willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
Have a BMI (body mass index) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
Are capable of giving signed informed consent document. All participants in this study will receive Lorlatinib. Participants will be placed into 1 of 3 cohorts based on their hepatic (liver) function. Participants will take Lorlatinib once by mouth. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective. Participants will take part in this study for up to 35 days.